Found 18 matching trials
Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers PHASE3 The primary immunogenicity objective is to assess and compare the immunogen...
Show More Learn More & Join Trial
Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine PHASE3 Infants aged 9 months will be randomized to receive a meningococcal vaccine...
Show More Location
Centre pour le Developpement des Vaccins du Mali
Learn More & Join Trial
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine PHASE3 The primary objective was to evaluate the persistence of bactericidal antib...
Show More Location
Alabama Clinical Therapeutics 806 St. Vincent's Drive, Suite 615
Learn More & Join Trial
Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination PHASE3 The purpose/aim of this study is to assess the safety and antibody response...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose PHASE4 In this extension study, V59P20E1, the sponsor was planning to assess 5-yea...
Show More Location
82 Children s Inv Research Prgm (ChIRP) 2900 Medical Center Parkway, Ste. 300
Learn More & Join Trial
Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months PHASE2 The purpose of this study is to evaluate how well the immuno response again...
Show More Location
Clinical Trials Research Center
Learn More & Join Trial
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life PHASE3 The purpose of this study was to assess immunogenicity of a 3-dose versus 4...
Show More Location
Multiple Locations
Learn More & Join Trial
Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old PHASE2 The purpose of this study is to evaluate the immunogenicity, safety and rea...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study N/A This safety surveillance study of GlaxoSmithKline's quadrivalent meningococ...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Comparison of Two Meningococcal ACWY Conjugate Vaccines PHASE2 There is evidence of waning immunity in individuals vaccinated against meni...
Show More Location
Multiple General Practice surgeries
Learn More & Join Trial